Bristol-Myers Squibb (BMY)
NYSE: BMY
· Real-Time Price · USD
49.95
-0.62 (-1.23%)
At close: May 05, 2025, 3:59 PM
49.99
0.07%
After-hours: May 05, 2025, 07:56 PM EDT
-1.23% (1D)
| Bid | 49.99 |
| Market Cap | 101.66B |
| Revenue (ttm) | 47.64B |
| Net Income (ttm) | 5.42B |
| EPS (ttm) | 2.68 |
| PE Ratio (ttm) | 18.64 |
| Forward PE | 8.09 |
| Analyst | Hold |
| Ask | 50.02 |
| Volume | 7,504,014 |
| Avg. Volume (20D) | 13,972,935 |
| Open | 50.47 |
| Previous Close | 50.57 |
| Day's Range | 49.34 - 50.58 |
| 52-Week Range | 39.35 - 63.33 |
| Beta | 0.41 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for th...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 1, 1972
Employees 34,100
Stock Exchange NYSE
Ticker Symbol BMY
Website https://www.bms.com
Analyst Forecast
According to 16 analyst ratings, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $61, which is an increase of 22.11% from the latest price.
Stock Forecasts1 week ago
-2.61%
Bristol-Myers Squibb shares are trading lower afte...
Unlock content with
Pro Subscription
1 week ago
+1.8%
Bristol-Myers Squibb shares are trading lower after the company announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia did not reach the threshold for statistical significance for the primary endpoint.
